

ASX ANNOUNCEMENT

21 September 2026

Date of Annual General Meeting – 25 November 2026

Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce, in accordance with Listing Rule 3.13.1, that the date of its AGM will be 25 November 2026.

In accordance with Clarity’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is 7 October 2026.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be sent to shareholders. The Notice of Meeting will also be available on the ASX Company Announcements Platform and on the Company’s website.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Executive Chairperson

ataylor@claritypharm.com

Lisa Sadetskaya

Director, Corporate Communications

lisa@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.